English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The etiology of irritable bowel syndrome (IBS) and dysmotility has not been well-established. Organic, pathognomic changes have not been described. Recently, Ohlsson et al1 suggested that higher levels of gonadotropin-releasing hormone (GnRH) IgM antibodies in serum were detected in patients with IBS and dysmotility, but not in organic gastrointestinal (GI) diseases, compared with healthy controls. They evaluated the presence of IgM and IgG antibodies against GnRH in serum using an ELISA method from healthy subjects and patients with GI diseases. The prevalence of GnRH IgM antibodies were higher in IBS and dysmotility patients than those in healthy controls (42% vs 23%, P = 0.008), and the expressed levels were higher (P = 0.000). Patients with celiac disease or inflammatory bowel disease had the same or lower levels of antibodies.  The authors concluded that antibodies against GnRH were common in patients with IBS and dysmotility, but not in organic diseases, compared with healthy controls, which might explain the symptoms in a subgroup of patients with these diseases. These findings suggested that IBS and dysmotility to some extent might be of an autoimmune origin.

Dose Irritable Bowel Syndrome and Dysmotility Have an Autoimmune Origin? (Neurogastroenterol Motil 2011;23:1000-1006, e459)